Ralimetinib,
862505-00-8,
LY-2228820 free base,
UNII-73I34XW4HD,
73I34XW4HD,
5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine,
LY 2228820,
C24H29FN6,
5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate,
Ralimetinib [USAN:INN],
LY2228820 free base,
Ralimetinib (USAN/INN),
GTPL7959,
SCHEMBL3989306,
CHEMBL2364626,
SCHEMBL13826263,
DTXSID00235456,
XPPBBJCBDOEXDN-UHFFFAOYSA-N,
BCPP000180,
BCP02033,
2526AH,
ABP000309,
ABP000548,
ZINC34630490,
AKOS027282678,
BCP9000871,
DB11787,
SB16635,
NCGC00346537-01,
NCGC00346537-05,
3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-,
4CA-0774,
DB-076584,
FT-0727743,
LY2228820/,
X7400,
LY-22288220,
D10658,
LY2228820/LY-2228820/,
5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine,
5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine,
5-[2-tert-butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)imidazo[5,4-b]pyridin-2-amine,
D08WYH,
D0U1WA,
LY-2228820 mesylate,
LY2228820,
LY-2228820.2MsOH,
862505-00-8 (free base),
LY-2228820,
CID11539025,
CID 11539025,
LY-479754,
LY-2180895,
LY-2211877,
LY-2231377,
LY-2322600,
P38 MAP kinase inhibitors (inflammation, cancer), Lilly,
(1R,2R)-2-(4'-(3-phenylureido)biphenylcarbonyl)cyclopentanecarboxylic acid,
862507-23-1,
959122-11-3,